Cost-effective Biomarkers in the Management of HIV Disease

The disease burden of human immunodeficiency virus (HIV) is substantially more prevalent among residents of the sub-Saharan Africa and Asia. The availability and affordability of highly active antiretroviral therapy (HAART) have significantly reduced the mortality among HIV-1 infected population increase their life expectancy and quality of life. However the poor financial conditions and lack of costly infrastructure in the developing countries hinder regular monitoring of HIV-1 RNA (viral load) and CD4+ T-lymphocyte cell count (TCD4+ cell count). Under these circumstances there is an increasing need for alternate biomarkers for monitoring the progression of the disease and patient management. Albumin hemoglobin (Hb) dehydroepiandrosterone sulfate (DHEA-S) red blood cell (RBC) count erythrocyte sedimentation rate (ESR) plasma highly-sensitive C-reactive protein (hs-CRP) hematocrit (Hct) total lymphocyte count (TLC) are some of the alternate biomarkers with proven utility in the assessment of disease progression.